Home Healthcare Pharmaceuticals Thyroid Cancer Drugs Market

Thyroid Cancer Drugs Market Size, Share & Trends Analysis Report By Type (Papillary Thyroid Cancer, Follicular Thyroid Cancer, Medullary Thyroid Cancer, Anaplastic Thyroid Cancer), By Treatment (Medication, Chemotherapy, Radioactive Iodine Therapy, Hormone Therapy), By Drug Type (Sorafenib, Vandetanib, Cabozantinib, Lenvatini, Sodium Iodide I-131, Dabrafenib, Trametinib), By Route of Administration (Oral, Injectable), By End Users (Hospitals, Homecare, Specialty Clinics), By Region (North America, Europe, APAC, Middle East and Africa, LATAM), Forecasts, 2026-2034

Last Updated: August 13, 2026 | Author: Mitiksha Koul | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Table Of Content

  1. Executive Summary
  2. Research Scope & Segmentation
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
  3. Market Opportunity Assessment
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
  4. Market Trends
    1. Drivers
    2. Market Warning Factors
    3. Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
  5. Market Assessment
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
  6. Thyroid Cancer Drugs Market Size Analysis
    1. Introduction
    2. Thyroid Cancer Drugs Market Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
      1. Papillary Thyroid Cancer
      2. Follicular Thyroid Cancer
      3. Hurthle Cell Cancer
      4. Medullary Thyroid Cancer (MTC)
      5. Anaplastic Thyroid Cancer
    3. Thyroid Cancer Drugs Market Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
      1. Medication
      2. Chemotherapy
      3. Radioactive Iodine (Radioiodine) Therapy
      4. Hormone Therapy
    4. Thyroid Cancer Drugs Market Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
      1. Thyroid Desiccated
      2. Sorafenib
      3. Thyrotropin Alfa
      4. Vandetanib
      5. Doxorubicin
      6. Cabozantinib
      7. Lenvatini
      8. Sodium Iodide I-131
      9. Dabrafenib
      10. Trametinib
      11. Others
    5. Thyroid Cancer Drugs Market Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
      1. Oral
      2. Injectable
      3. Others
    6. Thyroid Cancer Drugs Market Market Size & Forecast By End-Users 2022-2034 (USD MILLION/ Units)
      1. Hospitals
      2. Homecare
      3. Specialty Clinics
      4. Others
  7. North America Thyroid Cancer Drugs Market Size Analysis
    1. Introduction
    2. Thyroid Cancer Drugs Market Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
      1. Papillary Thyroid Cancer
      2. Follicular Thyroid Cancer
      3. Hurthle Cell Cancer
      4. Medullary Thyroid Cancer (MTC)
      5. Anaplastic Thyroid Cancer
    3. Thyroid Cancer Drugs Market Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
      1. Medication
      2. Chemotherapy
      3. Radioactive Iodine (Radioiodine) Therapy
      4. Hormone Therapy
    4. Thyroid Cancer Drugs Market Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
      1. Thyroid Desiccated
      2. Sorafenib
      3. Thyrotropin Alfa
      4. Vandetanib
      5. Doxorubicin
      6. Cabozantinib
      7. Lenvatini
      8. Sodium Iodide I-131
      9. Dabrafenib
      10. Trametinib
      11. Others
    5. Thyroid Cancer Drugs Market Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
      1. Oral
      2. Injectable
      3. Others
    6. Thyroid Cancer Drugs Market Market Size & Forecast By End-Users 2022-2034 (USD MILLION/ Units)
      1. Hospitals
      2. Homecare
      3. Specialty Clinics
      4. Others
    7. U.S.
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
      3. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication
        2. Chemotherapy
        3. Radioactive Iodine (Radioiodine) Therapy
        4. Hormone Therapy
      4. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Thyroid Desiccated
        2. Sorafenib
        3. Thyrotropin Alfa
        4. Vandetanib
        5. Doxorubicin
        6. Cabozantinib
        7. Lenvatini
        8. Sodium Iodide I-131
        9. Dabrafenib
        10. Trametinib
        11. Others
      5. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      6. Market Size & Forecast By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
    8. Canada
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
      3. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication
        2. Chemotherapy
        3. Radioactive Iodine (Radioiodine) Therapy
        4. Hormone Therapy
      4. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Thyroid Desiccated
        2. Sorafenib
        3. Thyrotropin Alfa
        4. Vandetanib
        5. Doxorubicin
        6. Cabozantinib
        7. Lenvatini
        8. Sodium Iodide I-131
        9. Dabrafenib
        10. Trametinib
        11. Others
      5. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      6. Market Size & Forecast By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
  8. Europe Thyroid Cancer Drugs Market Size Analysis
    1. Introduction
    2. Thyroid Cancer Drugs Market Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
      1. Papillary Thyroid Cancer
      2. Follicular Thyroid Cancer
      3. Hurthle Cell Cancer
      4. Medullary Thyroid Cancer (MTC)
      5. Anaplastic Thyroid Cancer
    3. Thyroid Cancer Drugs Market Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
      1. Medication
      2. Chemotherapy
      3. Radioactive Iodine (Radioiodine) Therapy
      4. Hormone Therapy
    4. Thyroid Cancer Drugs Market Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
      1. Thyroid Desiccated
      2. Sorafenib
      3. Thyrotropin Alfa
      4. Vandetanib
      5. Doxorubicin
      6. Cabozantinib
      7. Lenvatini
      8. Sodium Iodide I-131
      9. Dabrafenib
      10. Trametinib
      11. Others
    5. Thyroid Cancer Drugs Market Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
      1. Oral
      2. Injectable
      3. Others
    6. Thyroid Cancer Drugs Market Market Size & Forecast By End-Users 2022-2034 (USD MILLION/ Units)
      1. Hospitals
      2. Homecare
      3. Specialty Clinics
      4. Others
    7. U.K.
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
      3. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication
        2. Chemotherapy
        3. Radioactive Iodine (Radioiodine) Therapy
        4. Hormone Therapy
      4. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Thyroid Desiccated
        2. Sorafenib
        3. Thyrotropin Alfa
        4. Vandetanib
        5. Doxorubicin
        6. Cabozantinib
        7. Lenvatini
        8. Sodium Iodide I-131
        9. Dabrafenib
        10. Trametinib
        11. Others
      5. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      6. Market Size & Forecast By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
    8. Germany
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
      3. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication
        2. Chemotherapy
        3. Radioactive Iodine (Radioiodine) Therapy
        4. Hormone Therapy
      4. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Thyroid Desiccated
        2. Sorafenib
        3. Thyrotropin Alfa
        4. Vandetanib
        5. Doxorubicin
        6. Cabozantinib
        7. Lenvatini
        8. Sodium Iodide I-131
        9. Dabrafenib
        10. Trametinib
        11. Others
      5. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      6. Market Size & Forecast By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
    9. France
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
      3. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication
        2. Chemotherapy
        3. Radioactive Iodine (Radioiodine) Therapy
        4. Hormone Therapy
      4. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Thyroid Desiccated
        2. Sorafenib
        3. Thyrotropin Alfa
        4. Vandetanib
        5. Doxorubicin
        6. Cabozantinib
        7. Lenvatini
        8. Sodium Iodide I-131
        9. Dabrafenib
        10. Trametinib
        11. Others
      5. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      6. Market Size & Forecast By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
    10. Spain
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
      3. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication
        2. Chemotherapy
        3. Radioactive Iodine (Radioiodine) Therapy
        4. Hormone Therapy
      4. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Thyroid Desiccated
        2. Sorafenib
        3. Thyrotropin Alfa
        4. Vandetanib
        5. Doxorubicin
        6. Cabozantinib
        7. Lenvatini
        8. Sodium Iodide I-131
        9. Dabrafenib
        10. Trametinib
        11. Others
      5. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      6. Market Size & Forecast By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
    11. Italy
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
      3. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication
        2. Chemotherapy
        3. Radioactive Iodine (Radioiodine) Therapy
        4. Hormone Therapy
      4. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Thyroid Desiccated
        2. Sorafenib
        3. Thyrotropin Alfa
        4. Vandetanib
        5. Doxorubicin
        6. Cabozantinib
        7. Lenvatini
        8. Sodium Iodide I-131
        9. Dabrafenib
        10. Trametinib
        11. Others
      5. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      6. Market Size & Forecast By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
    12. Russia
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
      3. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication
        2. Chemotherapy
        3. Radioactive Iodine (Radioiodine) Therapy
        4. Hormone Therapy
      4. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Thyroid Desiccated
        2. Sorafenib
        3. Thyrotropin Alfa
        4. Vandetanib
        5. Doxorubicin
        6. Cabozantinib
        7. Lenvatini
        8. Sodium Iodide I-131
        9. Dabrafenib
        10. Trametinib
        11. Others
      5. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      6. Market Size & Forecast By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
    13. Nordic
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
      3. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication
        2. Chemotherapy
        3. Radioactive Iodine (Radioiodine) Therapy
        4. Hormone Therapy
      4. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Thyroid Desiccated
        2. Sorafenib
        3. Thyrotropin Alfa
        4. Vandetanib
        5. Doxorubicin
        6. Cabozantinib
        7. Lenvatini
        8. Sodium Iodide I-131
        9. Dabrafenib
        10. Trametinib
        11. Others
      5. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      6. Market Size & Forecast By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
    14. Benelux
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
      3. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication
        2. Chemotherapy
        3. Radioactive Iodine (Radioiodine) Therapy
        4. Hormone Therapy
      4. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Thyroid Desiccated
        2. Sorafenib
        3. Thyrotropin Alfa
        4. Vandetanib
        5. Doxorubicin
        6. Cabozantinib
        7. Lenvatini
        8. Sodium Iodide I-131
        9. Dabrafenib
        10. Trametinib
        11. Others
      5. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      6. Market Size & Forecast By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
    15. Rest of Europe
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
      3. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication
        2. Chemotherapy
        3. Radioactive Iodine (Radioiodine) Therapy
        4. Hormone Therapy
      4. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Thyroid Desiccated
        2. Sorafenib
        3. Thyrotropin Alfa
        4. Vandetanib
        5. Doxorubicin
        6. Cabozantinib
        7. Lenvatini
        8. Sodium Iodide I-131
        9. Dabrafenib
        10. Trametinib
        11. Others
      5. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      6. Market Size & Forecast By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
  9. APAC Thyroid Cancer Drugs Market Size Analysis
    1. Introduction
    2. Thyroid Cancer Drugs Market Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
      1. Papillary Thyroid Cancer
      2. Follicular Thyroid Cancer
      3. Hurthle Cell Cancer
      4. Medullary Thyroid Cancer (MTC)
      5. Anaplastic Thyroid Cancer
    3. Thyroid Cancer Drugs Market Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
      1. Medication
      2. Chemotherapy
      3. Radioactive Iodine (Radioiodine) Therapy
      4. Hormone Therapy
    4. Thyroid Cancer Drugs Market Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
      1. Thyroid Desiccated
      2. Sorafenib
      3. Thyrotropin Alfa
      4. Vandetanib
      5. Doxorubicin
      6. Cabozantinib
      7. Lenvatini
      8. Sodium Iodide I-131
      9. Dabrafenib
      10. Trametinib
      11. Others
    5. Thyroid Cancer Drugs Market Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
      1. Oral
      2. Injectable
      3. Others
    6. Thyroid Cancer Drugs Market Market Size & Forecast By End-Users 2022-2034 (USD MILLION/ Units)
      1. Hospitals
      2. Homecare
      3. Specialty Clinics
      4. Others
    7. China
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
      3. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication
        2. Chemotherapy
        3. Radioactive Iodine (Radioiodine) Therapy
        4. Hormone Therapy
      4. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Thyroid Desiccated
        2. Sorafenib
        3. Thyrotropin Alfa
        4. Vandetanib
        5. Doxorubicin
        6. Cabozantinib
        7. Lenvatini
        8. Sodium Iodide I-131
        9. Dabrafenib
        10. Trametinib
        11. Others
      5. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      6. Market Size & Forecast By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
    8. Korea
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
      3. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication
        2. Chemotherapy
        3. Radioactive Iodine (Radioiodine) Therapy
        4. Hormone Therapy
      4. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Thyroid Desiccated
        2. Sorafenib
        3. Thyrotropin Alfa
        4. Vandetanib
        5. Doxorubicin
        6. Cabozantinib
        7. Lenvatini
        8. Sodium Iodide I-131
        9. Dabrafenib
        10. Trametinib
        11. Others
      5. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      6. Market Size & Forecast By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
    9. Japan
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
      3. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication
        2. Chemotherapy
        3. Radioactive Iodine (Radioiodine) Therapy
        4. Hormone Therapy
      4. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Thyroid Desiccated
        2. Sorafenib
        3. Thyrotropin Alfa
        4. Vandetanib
        5. Doxorubicin
        6. Cabozantinib
        7. Lenvatini
        8. Sodium Iodide I-131
        9. Dabrafenib
        10. Trametinib
        11. Others
      5. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      6. Market Size & Forecast By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
    10. India
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
      3. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication
        2. Chemotherapy
        3. Radioactive Iodine (Radioiodine) Therapy
        4. Hormone Therapy
      4. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Thyroid Desiccated
        2. Sorafenib
        3. Thyrotropin Alfa
        4. Vandetanib
        5. Doxorubicin
        6. Cabozantinib
        7. Lenvatini
        8. Sodium Iodide I-131
        9. Dabrafenib
        10. Trametinib
        11. Others
      5. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      6. Market Size & Forecast By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
    11. Australia
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
      3. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication
        2. Chemotherapy
        3. Radioactive Iodine (Radioiodine) Therapy
        4. Hormone Therapy
      4. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Thyroid Desiccated
        2. Sorafenib
        3. Thyrotropin Alfa
        4. Vandetanib
        5. Doxorubicin
        6. Cabozantinib
        7. Lenvatini
        8. Sodium Iodide I-131
        9. Dabrafenib
        10. Trametinib
        11. Others
      5. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      6. Market Size & Forecast By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
    12. Singapore
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
      3. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication
        2. Chemotherapy
        3. Radioactive Iodine (Radioiodine) Therapy
        4. Hormone Therapy
      4. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Thyroid Desiccated
        2. Sorafenib
        3. Thyrotropin Alfa
        4. Vandetanib
        5. Doxorubicin
        6. Cabozantinib
        7. Lenvatini
        8. Sodium Iodide I-131
        9. Dabrafenib
        10. Trametinib
        11. Others
      5. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      6. Market Size & Forecast By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
    13. Taiwan
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
      3. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication
        2. Chemotherapy
        3. Radioactive Iodine (Radioiodine) Therapy
        4. Hormone Therapy
      4. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Thyroid Desiccated
        2. Sorafenib
        3. Thyrotropin Alfa
        4. Vandetanib
        5. Doxorubicin
        6. Cabozantinib
        7. Lenvatini
        8. Sodium Iodide I-131
        9. Dabrafenib
        10. Trametinib
        11. Others
      5. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      6. Market Size & Forecast By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
    14. South East Asia
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
      3. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication
        2. Chemotherapy
        3. Radioactive Iodine (Radioiodine) Therapy
        4. Hormone Therapy
      4. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Thyroid Desiccated
        2. Sorafenib
        3. Thyrotropin Alfa
        4. Vandetanib
        5. Doxorubicin
        6. Cabozantinib
        7. Lenvatini
        8. Sodium Iodide I-131
        9. Dabrafenib
        10. Trametinib
        11. Others
      5. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      6. Market Size & Forecast By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
    15. Rest of Asia-Pacific
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
      3. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication
        2. Chemotherapy
        3. Radioactive Iodine (Radioiodine) Therapy
        4. Hormone Therapy
      4. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Thyroid Desiccated
        2. Sorafenib
        3. Thyrotropin Alfa
        4. Vandetanib
        5. Doxorubicin
        6. Cabozantinib
        7. Lenvatini
        8. Sodium Iodide I-131
        9. Dabrafenib
        10. Trametinib
        11. Others
      5. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      6. Market Size & Forecast By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
  10. Middle East and Africa Thyroid Cancer Drugs Market Size Analysis
    1. Introduction
    2. Thyroid Cancer Drugs Market Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
      1. Papillary Thyroid Cancer
      2. Follicular Thyroid Cancer
      3. Hurthle Cell Cancer
      4. Medullary Thyroid Cancer (MTC)
      5. Anaplastic Thyroid Cancer
    3. Thyroid Cancer Drugs Market Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
      1. Medication
      2. Chemotherapy
      3. Radioactive Iodine (Radioiodine) Therapy
      4. Hormone Therapy
    4. Thyroid Cancer Drugs Market Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
      1. Thyroid Desiccated
      2. Sorafenib
      3. Thyrotropin Alfa
      4. Vandetanib
      5. Doxorubicin
      6. Cabozantinib
      7. Lenvatini
      8. Sodium Iodide I-131
      9. Dabrafenib
      10. Trametinib
      11. Others
    5. Thyroid Cancer Drugs Market Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
      1. Oral
      2. Injectable
      3. Others
    6. Thyroid Cancer Drugs Market Market Size & Forecast By End-Users 2022-2034 (USD MILLION/ Units)
      1. Hospitals
      2. Homecare
      3. Specialty Clinics
      4. Others
    7. UAE
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
      3. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication
        2. Chemotherapy
        3. Radioactive Iodine (Radioiodine) Therapy
        4. Hormone Therapy
      4. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Thyroid Desiccated
        2. Sorafenib
        3. Thyrotropin Alfa
        4. Vandetanib
        5. Doxorubicin
        6. Cabozantinib
        7. Lenvatini
        8. Sodium Iodide I-131
        9. Dabrafenib
        10. Trametinib
        11. Others
      5. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      6. Market Size & Forecast By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
    8. Turkey
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
      3. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication
        2. Chemotherapy
        3. Radioactive Iodine (Radioiodine) Therapy
        4. Hormone Therapy
      4. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Thyroid Desiccated
        2. Sorafenib
        3. Thyrotropin Alfa
        4. Vandetanib
        5. Doxorubicin
        6. Cabozantinib
        7. Lenvatini
        8. Sodium Iodide I-131
        9. Dabrafenib
        10. Trametinib
        11. Others
      5. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      6. Market Size & Forecast By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
    9. Saudi Arabia
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
      3. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication
        2. Chemotherapy
        3. Radioactive Iodine (Radioiodine) Therapy
        4. Hormone Therapy
      4. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Thyroid Desiccated
        2. Sorafenib
        3. Thyrotropin Alfa
        4. Vandetanib
        5. Doxorubicin
        6. Cabozantinib
        7. Lenvatini
        8. Sodium Iodide I-131
        9. Dabrafenib
        10. Trametinib
        11. Others
      5. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      6. Market Size & Forecast By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
    10. South Africa
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
      3. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication
        2. Chemotherapy
        3. Radioactive Iodine (Radioiodine) Therapy
        4. Hormone Therapy
      4. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Thyroid Desiccated
        2. Sorafenib
        3. Thyrotropin Alfa
        4. Vandetanib
        5. Doxorubicin
        6. Cabozantinib
        7. Lenvatini
        8. Sodium Iodide I-131
        9. Dabrafenib
        10. Trametinib
        11. Others
      5. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      6. Market Size & Forecast By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
    11. Egypt
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
      3. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication
        2. Chemotherapy
        3. Radioactive Iodine (Radioiodine) Therapy
        4. Hormone Therapy
      4. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Thyroid Desiccated
        2. Sorafenib
        3. Thyrotropin Alfa
        4. Vandetanib
        5. Doxorubicin
        6. Cabozantinib
        7. Lenvatini
        8. Sodium Iodide I-131
        9. Dabrafenib
        10. Trametinib
        11. Others
      5. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      6. Market Size & Forecast By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
    12. Nigeria
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
      3. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication
        2. Chemotherapy
        3. Radioactive Iodine (Radioiodine) Therapy
        4. Hormone Therapy
      4. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Thyroid Desiccated
        2. Sorafenib
        3. Thyrotropin Alfa
        4. Vandetanib
        5. Doxorubicin
        6. Cabozantinib
        7. Lenvatini
        8. Sodium Iodide I-131
        9. Dabrafenib
        10. Trametinib
        11. Others
      5. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      6. Market Size & Forecast By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
    13. Rest of MEA
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
      3. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication
        2. Chemotherapy
        3. Radioactive Iodine (Radioiodine) Therapy
        4. Hormone Therapy
      4. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Thyroid Desiccated
        2. Sorafenib
        3. Thyrotropin Alfa
        4. Vandetanib
        5. Doxorubicin
        6. Cabozantinib
        7. Lenvatini
        8. Sodium Iodide I-131
        9. Dabrafenib
        10. Trametinib
        11. Others
      5. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      6. Market Size & Forecast By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
  11. LATAM Thyroid Cancer Drugs Market Size Analysis
    1. Introduction
    2. Thyroid Cancer Drugs Market Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
      1. Papillary Thyroid Cancer
      2. Follicular Thyroid Cancer
      3. Hurthle Cell Cancer
      4. Medullary Thyroid Cancer (MTC)
      5. Anaplastic Thyroid Cancer
    3. Thyroid Cancer Drugs Market Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
      1. Medication
      2. Chemotherapy
      3. Radioactive Iodine (Radioiodine) Therapy
      4. Hormone Therapy
    4. Thyroid Cancer Drugs Market Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
      1. Thyroid Desiccated
      2. Sorafenib
      3. Thyrotropin Alfa
      4. Vandetanib
      5. Doxorubicin
      6. Cabozantinib
      7. Lenvatini
      8. Sodium Iodide I-131
      9. Dabrafenib
      10. Trametinib
      11. Others
    5. Thyroid Cancer Drugs Market Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
      1. Oral
      2. Injectable
      3. Others
    6. Thyroid Cancer Drugs Market Market Size & Forecast By End-Users 2022-2034 (USD MILLION/ Units)
      1. Hospitals
      2. Homecare
      3. Specialty Clinics
      4. Others
    7. Brazil
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
      3. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication
        2. Chemotherapy
        3. Radioactive Iodine (Radioiodine) Therapy
        4. Hormone Therapy
      4. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Thyroid Desiccated
        2. Sorafenib
        3. Thyrotropin Alfa
        4. Vandetanib
        5. Doxorubicin
        6. Cabozantinib
        7. Lenvatini
        8. Sodium Iodide I-131
        9. Dabrafenib
        10. Trametinib
        11. Others
      5. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      6. Market Size & Forecast By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
    8. Mexico
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
      3. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication
        2. Chemotherapy
        3. Radioactive Iodine (Radioiodine) Therapy
        4. Hormone Therapy
      4. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Thyroid Desiccated
        2. Sorafenib
        3. Thyrotropin Alfa
        4. Vandetanib
        5. Doxorubicin
        6. Cabozantinib
        7. Lenvatini
        8. Sodium Iodide I-131
        9. Dabrafenib
        10. Trametinib
        11. Others
      5. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      6. Market Size & Forecast By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
    9. Argentina
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
      3. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication
        2. Chemotherapy
        3. Radioactive Iodine (Radioiodine) Therapy
        4. Hormone Therapy
      4. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Thyroid Desiccated
        2. Sorafenib
        3. Thyrotropin Alfa
        4. Vandetanib
        5. Doxorubicin
        6. Cabozantinib
        7. Lenvatini
        8. Sodium Iodide I-131
        9. Dabrafenib
        10. Trametinib
        11. Others
      5. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      6. Market Size & Forecast By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
    10. Chile
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
      3. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication
        2. Chemotherapy
        3. Radioactive Iodine (Radioiodine) Therapy
        4. Hormone Therapy
      4. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Thyroid Desiccated
        2. Sorafenib
        3. Thyrotropin Alfa
        4. Vandetanib
        5. Doxorubicin
        6. Cabozantinib
        7. Lenvatini
        8. Sodium Iodide I-131
        9. Dabrafenib
        10. Trametinib
        11. Others
      5. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      6. Market Size & Forecast By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
    11. Colombia
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
      3. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication
        2. Chemotherapy
        3. Radioactive Iodine (Radioiodine) Therapy
        4. Hormone Therapy
      4. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Thyroid Desiccated
        2. Sorafenib
        3. Thyrotropin Alfa
        4. Vandetanib
        5. Doxorubicin
        6. Cabozantinib
        7. Lenvatini
        8. Sodium Iodide I-131
        9. Dabrafenib
        10. Trametinib
        11. Others
      5. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      6. Market Size & Forecast By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
    12. Rest of LATAM
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. Papillary Thyroid Cancer
        2. Follicular Thyroid Cancer
        3. Hurthle Cell Cancer
        4. Medullary Thyroid Cancer (MTC)
        5. Anaplastic Thyroid Cancer
      3. Market Size & Forecast By Treatment 2022-2034 (USD MILLION/ Units)
        1. Medication
        2. Chemotherapy
        3. Radioactive Iodine (Radioiodine) Therapy
        4. Hormone Therapy
      4. Market Size & Forecast By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Thyroid Desiccated
        2. Sorafenib
        3. Thyrotropin Alfa
        4. Vandetanib
        5. Doxorubicin
        6. Cabozantinib
        7. Lenvatini
        8. Sodium Iodide I-131
        9. Dabrafenib
        10. Trametinib
        11. Others
      5. Market Size & Forecast By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Injectable
        3. Others
      6. Market Size & Forecast By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Homecare
        3. Specialty Clinics
        4. Others
  12. Competitive Landscape
    1. Thyroid Cancer Drugs Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    3. Tier Structure Analysis
    4. Recent Developments
  13. Market Players Assessment
    1. Mylan N.V. 
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Bristol-Myers Squibb Company 
    3. Teva Pharmaceutical Industries Ltd 
    4. Jerome Stevens Pharmaceuticals Inc 
    5. Baxter 
    6. Abbott 
    7. Celgene Corporation 
    8. AstraZeneca 
    9. GlaxoSmithKline plc 
    10. Eisai Co. Ltd 
    11. Takeda Pharmaceutical Company Ltd
    12. Biovista
    13. Cytori Therapeutics Inc
    14. Bayer AG 
    15. Novartis AG 
    16. Bio-Path Holdings Inc. 
    17. Vascular Biogenics 
  14. Research Methodology
    1. Research Data
      1. Secondary Data
        1. Major Secondary Sources
        2. Key Data from Secondary Sources
      2. Primary Data
        1. Key Data from Primary Sources
        2. Breakdown of Primaries
      3. Secondary And Primary Research
        1. Key Industry Insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
  15. Appendix
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  16. Disclaimer
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.